SPRAVATO TREATMENT | CLERMONT, FL
SPRAVATO® Treatment for Treatment-Resistant Depression in Clermont, FL
When traditional antidepressants haven’t provided enough relief, another treatment option may be available.
SPRAVATO® (esketamine) is an FDA-approved prescription nasal spray for adults with treatment-resistant depression. At A New Hope Psychiatric Services, our goal is to help you explore appropriate treatment options through personalized psychiatric care and clinical evaluation.
What Happens When Antidepressants Aren't Enough?
When depression symptoms continue despite treatment, it may be time to explore additional options.
Not everyone experiences sufficient improvement with their first antidepressant. Some people continue to struggle with depression even after trying multiple medications. This may be a sign of treatment-resistant depression (TRD), generally defined as depression that has not responded adequately to at least two appropriate antidepressant treatments.
Review Past Treatments
Understand which antidepressants you've tried, how long you've taken them, and how well they worked.
Understand Ongoing Symptoms
Evaluate persistent depression symptoms and how they may affect your daily life.
Explore Other Options
Discuss additional evidence-based approaches, including SPRAVATO when clinically appropriate.
Not finding enough relief doesn't mean you've run out of options. A comprehensive psychiatric evaluation can help determine the next step in your care.
Illustrative healthcare environment.
What Is SPRAVATO® (Esketamine)?
A Different Approach to Treating Depression
SPRAVATO® (esketamine) is an FDA-approved prescription nasal spray for adults with treatment-resistant depression. It is administered under the supervision of healthcare professionals in a certified treatment setting.
Unlike many traditional antidepressants, SPRAVATO acts on the brain's glutamate system. Its suitability depends on an individual clinical assessment, including treatment history and medical considerations.
FDA-Approved Treatment
Approved for treatment-resistant depression in adults.
Different Mechanism of Action
Acts on the glutamate system differently from many traditional antidepressants.
Supervised Administration
Administered in a certified healthcare setting under professional observation.
Required Safety Monitoring
Patients require monitoring for at least two hours after each administration.
Important to know: SPRAVATO is not suitable for everyone and has serious risks, including boxed warnings. A qualified healthcare professional must evaluate treatment suitability.
Who May Be Eligible for SPRAVATO®?
Every Treatment Decision Begins With Understanding You.
SPRAVATO® (esketamine) is an FDA-approved prescription treatment for adults with treatment-resistant depression.
Treatment-resistant depression generally describes depression that has not responded adequately to at least two appropriate antidepressant trials.
A healthcare professional considers your diagnosis, treatment history, medical conditions, current medications, and possible risks before determining whether a treatment is appropriate.
What Does an Evaluation Consider?
Depression Diagnosis
A clinician reviews the diagnosis, current symptoms, and relevant psychiatric history.
Previous Treatments
Previous antidepressant trials, treatment duration, response, and tolerability are considered.
Medical History & Safety
Blood pressure, relevant health conditions, medications, and contraindications require review.
Individual Clinical Assessment
A qualified prescriber weighs potential benefits and risks to determine an appropriate treatment plan.
Treatment Decisions Require Professional Medical Evaluation
SPRAVATO is not appropriate for everyone with depression. It has serious risks and must be administered in a certified healthcare setting. Review official prescribing information for complete safety details.
Read Official Prescribing InformationWhat to Expect During SPRAVATO® Treatment
Understanding each step, from initial clinical evaluation to supervised treatment and ongoing care.
SPRAVATO® (esketamine) treatment follows a structured clinical process that includes assessing treatment suitability, planning care, supervised administration, and monitoring. The process is individualized according to each patient's needs and the prescribing clinician's recommendations.
Initial Psychiatric Evaluation
A qualified healthcare professional reviews your depression symptoms, previous antidepressant treatments, medical history, current medications, and potential treatment risks.
Personalized Treatment Planning
If SPRAVATO is considered appropriate, the prescribing clinician discusses the treatment schedule, potential side effects, safety precautions, and required monitoring.
Supervised Treatment Sessions
SPRAVATO is administered in a REMS-certified healthcare setting under direct professional supervision. Patients are monitored for at least two hours after each administration.
Ongoing Assessment & Follow-Up
The treating clinician reviews treatment response, side effects, and overall progress to determine whether continued treatment is clinically appropriate.
Important Information About Treatment Visits
SPRAVATO requires monitoring for at least two hours after each treatment session. Patients must arrange transportation home and must not drive or operate machinery until the next day after a restful sleep. Healthcare professionals determine when patients are clinically stable to leave the treatment setting.
Understanding SPRAVATO® Safety & Side Effects
Making informed treatment decisions starts with understanding the potential risks, side effects, and safety precautions.
SPRAVATO® (esketamine) is a prescription treatment that requires careful medical supervision. Before treatment, a healthcare professional reviews relevant medical conditions, medications, contraindications, and individual risks to determine whether it may be appropriate.
Possible Side Effects
Commonly reported effects include dizziness, nausea, sedation, changes in perception, increased blood pressure, and headache. Individual experiences may vary.
Serious Safety Warnings
SPRAVATO has boxed warnings for sedation, dissociation, respiratory depression, abuse and misuse, and suicidal thoughts and behaviors.
Required Monitoring
Patients must be monitored for at least two hours after each administration in a certified healthcare setting. Healthcare professionals assess clinical stability before discharge.
Transportation & Recovery
Patients must arrange transportation home after treatment. Driving or operating machinery is not permitted until the next day after a restful sleep.
SPRAVATO® Boxed Warnings
SPRAVATO can cause serious adverse reactions, including sedation, dissociation, and respiratory depression. There is a risk of abuse and misuse. Antidepressant treatment also carries a warning about increased risk of suicidal thoughts and behaviors in pediatric and young adult patients.
SPRAVATO is only available through a restricted Risk Evaluation and Mitigation Strategy (REMS) program. It must be administered under healthcare professional supervision with required monitoring.
This is a summary, not the complete boxed warning or full prescribing information.
Additional Medical Precautions
SPRAVATO has contraindications, including certain aneurysmal vascular diseases, arteriovenous malformations, a history of intracerebral hemorrhage, and hypersensitivity to esketamine, ketamine, or excipients. Blood pressure and other clinical factors must be assessed before treatment.
Discuss all medications, medical conditions, pregnancy considerations, and relevant health history with your prescribing clinician. Treatment suitability requires an individualized medical evaluation.
Read Official SPRAVATO Safety InformationThis content is for general educational purposes and does not replace professional medical advice, the FDA Medication Guide, or the complete prescribing information.
Taking the Next Step Toward SPRAVATO® Evaluation
Understanding your insurance requirements and treatment history is an important part of exploring SPRAVATO® (esketamine).
Coverage varies by insurance plan, and some plans require prior authorization or documentation of previous antidepressant treatments. Our proposed evaluation pathway is designed to help patients understand the next steps, from their initial inquiry to a professional clinical assessment.
Request Information
Contact A New Hope to ask about SPRAVATO evaluation availability and the inquiry process.
Initial Screening
The care team may request relevant information about your treatment history through the practice's secure intake process.
Insurance Verification
Relevant benefits, coverage criteria, and any prior authorization requirements can be reviewed before treatment planning.
Clinical Evaluation
When appropriate, schedule an evaluation with a qualified provider to discuss treatment suitability, risks, and available options.
Start With a Conversation.
Contact A New Hope Psychiatric Services for information about psychiatric evaluations and the SPRAVATO inquiry process.
Contact Our TeamImportant Coverage Information
Insurance verification does not guarantee authorization, coverage, payment, or treatment eligibility. Treatment decisions are based on an individual clinical evaluation.
Your Questions About SPRAVATO®, Answered
Understanding depression treatment options can help you have more informed conversations with your healthcare provider.
What is SPRAVATO® used for?
SPRAVATO® (esketamine) is an FDA-approved prescription nasal spray for adults with treatment-resistant depression, either alone or alongside an oral antidepressant. It also has a separate approved indication for certain depressive symptoms in adults with major depressive disorder when used with an oral antidepressant. Clinical evaluation is required.
What is treatment-resistant depression?
Treatment-resistant depression generally refers to depression that has not improved adequately after at least two appropriate antidepressant treatment trials. A healthcare professional reviews previous treatments and symptoms before making a clinical determination.
How is SPRAVATO different from traditional antidepressants?
SPRAVATO contains esketamine, which acts on the brain's glutamate system through NMDA receptor antagonism. This differs from the primary mechanisms of many commonly prescribed antidepressants. Each medication has its own risks, benefits, and clinical considerations.
Who may be considered for SPRAVATO?
For treatment-resistant depression, clinicians review an adult patient's diagnosis, previous antidepressant treatments, medical history, current medications, and treatment risks. SPRAVATO is not suitable for everyone.
Learn about clinical eligibilityCan SPRAVATO be administered at home?
No. SPRAVATO must be administered in a healthcare setting certified under the SPRAVATO REMS program, under direct healthcare professional supervision. Required observation follows every administration.
How long does a SPRAVATO appointment take?
Monitoring must continue for at least two hours after administration. Additional time may be needed for clinical checks and other appointment procedures. The healthcare team determines when a patient is clinically stable to leave.
What are the possible side effects?
Possible side effects include dizziness, nausea, sedation, changes in perception, headache, and increased blood pressure. SPRAVATO also carries serious boxed warnings and specific contraindications. Review all risks with your healthcare provider.
Read the safety sectionCan I drive after a SPRAVATO session?
Patients must arrange transportation home after treatment. Driving and operating machinery are not permitted until the next day after a restful sleep, according to the prescribing information.
Will insurance cover SPRAVATO?
Coverage depends on the insurance plan and applicable medical necessity criteria. Some plans require prior authorization or documentation of previous treatments. Insurance verification does not guarantee approval or payment.
Understand insurance verificationWhere can I learn about an initial psychiatric evaluation?
A New Hope Psychiatric Services provides information about comprehensive psychiatric evaluations and its general contact process. Patients can ask the practice about current services, appointment availability, and appropriate next steps.
Explore Psychiatric EvaluationsStill Have Questions?
Explore the practice's psychiatric services and contact information to learn more about available evaluation options.
Contact A New HopeOfficial Medication Information
For complete indications, warnings, side effects, contraindications, and precautions, review the current FDA Medication Guide.
View FDA Medication GuideEducational information only. Individual treatment decisions require assessment by a qualified healthcare professional.
Explore Your Next Steps in Depression Care.
When previous treatments haven't provided enough improvement, a comprehensive psychiatric evaluation can help you understand your available care options.
At A New Hope Psychiatric Services, we emphasize individualized assessment, informed treatment decisions, and collaborative mental healthcare. Contact our team to learn about psychiatric evaluations and available services.
Information on this page is educational and does not guarantee eligibility, insurance approval, or availability of a particular treatment. Treatment decisions require individual medical evaluation.